What did @chuggers actually say?
@chuggers crowned ipamorelin their top-ranked solo peptide, giving it an 8.5 for muscle building, an 8 for fat loss because it "promotes metabolism without hunger," a 9.5 for recovery, and a remarkable 9.8 for side effects. These are bold, specific numerical scores presented with real confidence, and they deserve specific scrutiny. The framing here is enthusiastic but not reckless on its face. Let's check what's behind the numbers.
Does the science back this up?
Partially, but the confidence in those scores outpaces the evidence considerably. Ipamorelin is a selective growth hormone secretagogue, meaning it triggers pulsatile GH release without significantly spiking cortisol or prolactin, which is genuinely a favorable profile compared to older GHRPs. That much is supported. But most of the human data is thin.
On fat loss without hunger: ipamorelin does not directly suppress appetite like GLP-1 agonists do. The "metabolism without hunger" framing borrows from the fact that ipamorelin doesn't appear to strongly stimulate ghrelin-related hunger signals the way GHRP-6 does. A 2001 study by Raun et al. in the European Journal of Endocrinology confirmed ipamorelin's selective GH-releasing action in pigs with minimal effect on hunger hormones. But that is not the same as "promotes metabolism" in a clinically meaningful way. The metabolic boost claim relies heavily on downstream GH effects, which are modest and dose-dependent.
Recovery at 9.5 is the most defensible score. GH pulses do support tissue repair, sleep quality, and collagen synthesis. But human RCT data specifically for ipamorelin's recovery effects is sparse. Most of what exists is animal data or inference from GH biology broadly.
What did they get wrong (or right)?
They got the side effect profile broadly right. Ipamorelin's selectivity is genuinely one of its better-documented characteristics. Unlike GHRP-2 or GHRP-6, it shows minimal cortisol elevation and low prolactin impact. A 1999 paper by Johansen et al. in Growth Hormone and IGF Research supported this selective action. Calling that a 9.8 is reasonable if you're grading relative to other GH secretagogues.
What they got wrong, or at least oversimplified: the fat loss score of 8 implies a direct, meaningful fat-burning effect. The actual mechanism is indirect. Elevated GH can shift substrate utilization toward fat oxidation over time, but this is not a strong acute fat loss signal. Calling it "fat loss" at an 8 without that caveat is misleading to an audience that may be looking for something closer to how semaglutide or even CJC-1295 stacks are described.
The muscle building score of 8.5 also runs ahead of the data. Human studies on ipamorelin specifically for hypertrophy are essentially absent in published literature. Extrapolating from GH physiology to a specific numerical score is not evidence-based scoring. It's educated guessing dressed up as a rating system.
What should you actually know?
Ipamorelin is not approved by the FDA for any indication. It is available through compounding pharmacies in some contexts, but it is classified as a research chemical and its legal and regulatory status varies. The FDA has taken action against compounders for certain peptides, and the landscape for compounded peptides is actively shifting.
If you are considering ipamorelin through a telehealth or clinical pathway, the conversation should include your baseline GH axis, any history of cancer or IGF-1-sensitive conditions, and realistic expectations. GH secretagogues are not a substitute for sleep, resistance training, or caloric management. The "metabolism boost" effect, where it exists, is subtle and cumulative, not dramatic.
The 9.8 side effect score is probably the most honest number in the video. Ipamorelin's tolerability profile is genuinely favorable compared to synthetic GH or peptides with broader receptor activity. But "minimal side effects" doesn't mean no side effects, and individual response varies. Water retention, transient fatigue, and injection site reactions are documented.
Anyone seeing this video should treat the numerical scores as one person's subjective framework, not clinical data. The enthusiasm is understandable. The precision of those scores is not warranted by the current literature.
Is ipamorelin actually 'S-tier' among peptides?
By the creator's own criteria, maybe. If you weight selectivity, tolerability, and a reasonable multi-domain effect profile, ipamorelin compares favorably to older GHRPs. The argument for it as a solo peptide is that it does several things without doing any of them badly. That's a coherent position.
But "S-tier" is a relative ranking in a category, peptides, where most of the human evidence is preliminary. Calling anything in this space S-tier without noting that caveat is a disservice to the audience. The better framing is that ipamorelin has a promising tolerability and mechanistic profile, warrants continued clinical research, and may have practical utility in supervised contexts. That's less exciting than S-tier, but it's what the data supports.